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Objectives: To review and compare current Health Technology Assessment (HTA) activities for medical devices (MDs) across European HTA institutions.
Methods: A comprehensive approach was adopted to identify institutions involved in HTA in European countries. We systematically searched institutional Web sites and other online
sources by using a structured tool to extract information on the role and link to decision making, structure, scope, process, methodological approach, and available HTA reports for
each included institution.
Results: Information was obtained from eighty-four institutions, forty-seven of which were analyzed. Fifty-four methodological documents from twenty-three agencies in eighteen
countries were identified. Only five agencies had separate documents for the assessment of MDs. A few agencies made separate provisions for the assessment of MDs in their
general methods. The amount of publicly available HTA reports on MDs varied by device category and agency remit.
Conclusions: Despite growing consensus on their importance and international initiatives, such as the EUnetHTA Core Model®, specific tools for the assessment of MDs are rarely
developed and implemented at the national level. Separate additional signposts incorporated in existing general methods guides may be sufficient for the evaluation of MDs.
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INTRODUCTION
Health Technology Assessment (HTA) as a decision support
tool for coverage has been most frequently formally established
to evaluate pharmaceuticals (1). The suitability of this method-
ology for medical devices (MDs) has been gaining interest as
a topic of scientific discourse, especially in light of the discus-
sion of the introduction of new regulatory provisions for their
market authorization (2). Europe is one of the biggest markets
for MDs, which encompass a broad and heterogeneous range
of technologies. According to the European Union, a medical
device is defined as “any instrument, apparatus, appliance, soft-
ware, material or other article, whether used alone or in com-
bination, including the software intended by its manufacturer
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to be used specifically for diagnostic and/or therapeutic pur-
poses and necessary for its proper application, intended by the
manufacturer to be used for human beings for the purpose of
diagnosis, prevention, monitoring, treatment or alleviation of
disease” (3).
There are different classifications of MDs ranging
from risk-based (such as the EU Directives 93/42/EEC &
90/385/EEC) to those incorporating financial elements (e.g.,
OECD System of Health Accounts) or aiming to facilitate com-
mon device identification (e.g., Global Medical Device Nomen-
clature). In a recent classification incorporating the HTA per-
spective (4), Henschke et al. argue that MDs can be divided
into three main groups: (i) assistive technology devices (di-
rectly used by patients, e.g., wheel chair), (ii) artificial body
parts (implanted by a medical procedure, e.g., stents), and (iii)
MDs for the assistance of medical professionals (e.g., PET/CT
scanner).
Currently, there is no overview of existing structural, pro-
cedural, and/or methodological approaches of HTA institutions
for assessing MDs in European countries. Previous compara-
tive research has looked, among other things, at HTA institu-
tional practice in general (5) mostly with an international focus
(6;7), concentrated on specific aspects of HTA such as eco-
nomic evaluation (8), focused on pharmaceuticals (9) or on
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selected emerging settings (10). Ciani et al. recently published
a relevant overview of practices among institutions outside the
European Union (11).
The aim of this work was to (i) identify institutions in-
volved in HTA of MDs in Europe and to (ii) explore their struc-
tural, procedural, and methodological characteristics, particu-
larly in regard to MD assessment.
METHODS
Selection of HTA Institutions
A comprehensive approach was adopted to identify institutions
involved in HTA in European countries. The identification pro-
cess was based on previous research (12), which was modified
to fit the project objectives. The membership lists of INAHTA,
EUnetHTA, HTAi, and HTAi Vortal Europe were combined
and supplemented by institutions identified in comparative arti-
cles published in this journal in 2011 and 2012. From the result-
ing pool, institutions from EUMember States and the European
Free Trade Association (EFTA) countries were included in the
analysis.
Data Collection
For each included institution, the institutional Web site and
other online sources (e.g., INAHTA Web site, where available)
were searched with the aim of obtaining relevant information
on structural, procedural, and methodological characteristics.
Information directly displayed on the Web site as well as up-
loaded documents were considered (see “Data Extraction”).
To supplement these findings, a systematic literature search
was performed in MEDLINE, EMBASE and the Cochrane Li-
brary. The search strategy consisted of a list of included insti-
tutions with both their original name and their preferred En-
glish translation, the type of technology, e.g., “MDs” and the
type of publication, for example, “methods” and “evaluation”
(an overview of the main search components is shown in Sup-
plementary Table 1; full search strategy is available on request).
The search was performed in September 2013. After removal of
duplicates, the remaining citations were screened for relevance.
Publications were included if they referred to the methodology
or process of HTA for MDs by an institution from the predeter-
mined pool. For this purpose, our underlying understanding of
MDs encompassed all three types described by Henschke et al.
(4) (see introduction), both for diagnostic and therapeutic pur-
poses. A 5-year window was selected to ensure up-to-dateness.
Only full-text documents were included. The selection of pub-
lications was performed in two steps (title-abstract and full-text
screening).
To gain more information on the health system context,
Health Systems in Transition country reports (latest version per
included country) available from the European Observatory on
Health Systems and Policies were also consulted.
Data Extraction
To systematize information collection, an extraction tool with
twenty items was developed based on Drummond’s key prin-
ciples for HTA programs (13). The tool captured the domain’s
role and link to decision making (e.g., institution’s place in the
country’s HTA system), structure (e.g., annual funding), scope
(e.g., types of technologies addressed), process (e.g., priority-
setting for topic selection), HTA report production (e.g., pro-
ducing/commissioning reports), and methodology (e.g., avail-
able methodological documents).
Once the overview of information on these domains was
completed, our research focused mainly on methodological ele-
ments. For this purpose, we screened and analyzed all method-
ological documents identified during the systematic informa-
tion collection using a second extraction tool, which also
incorporated elements from Drummond’s framework.
This second tool captured the domains assessment ele-
ments (e.g., clinical effectiveness), evidence procurement and
selection (e.g., manufacturer submissions), appraisal of evi-
dence quality (e.g., tools for appraisal), review process and
transparency (e.g., stakeholder involvement), re-assessment
(e.g., specific interval), knowledge exchange and transferabil-
ity (e.g., reports from HTA agencies), and cost and economic
evaluation (e.g., type of analysis). Both tools are available on
request.
Data Analysis
Every step of the process described above was performed inde-
pendently by two reviewer pairs. Discrepancies were resolved
by discussion and consensus. Based on the extracted informa-
tion, institution-specific profiles were compiled and aggregated
into two overview tables containing the most relevant informa-
tion (see Supplementary Tables 2 and 3). The main results are
presented below following further abstraction.
RESULTS
Selected HTA Institutions
The composed pool included eighty-four institutions after the
removal of duplicates (n = 99). In a first step, information
on all institutions was obtained from the Web sites and on-
line sources. Institutions were excluded from further analysis
if they (i) were not involved in general with HTA production
(n = 33; neither producing nor commissioning HTAs, e.g.,
funding/coordinating HTA activities); or (ii) focused only on
pharmaceuticals (n = 4). Forty-seven institutions were thus in-
cluded in the analysis (see Supplementary Figure 1).
Collected Institution-specific Data
Information on included institutions was supplemented by
the systematic literature search (Figure 1). The search yielded
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Figure 1. Flow chart of the publication selection process during the systematic literature search.
4,393 publications. After removal of duplicates and screening,
thirty-seven publications remained for analysis.
Role and Scope of Included Institutions
Table 1 presents selected information on the role and scope of
the included institutions. The majority of institutions (36 per-
cent; n = 17) represent governmental institutions, followed by
independent research entities which function as governmental
institutions (23 percent; n = 11).
The structural elements explored (not shown in Table 1)
comprised information regarding annual funding, number and
background of members/staff and resources explicitly dedi-
cated to MDs. None of the included institutions provides pub-
licly available information on all four aspects. Excluding con-
sultants and experts, staff numbers range from 8 (UTA) to more
than 500 (NICE) and vary according to institution remit. The
professional background of staff comprises a broad range and
encompasses nearly every scientific field related to health care.
Following the categorization of health technologies pro-
vided by Banta and Luce (14), 53 percent (n = 25) of in-
cluded institutions cover a broad range of technologies includ-
ing drugs, MDs, procedures, and systems (e.g., public health
programs). Eighty-seven percent (n = 41) address drugs, 83
percent (n = 39) procedures, and 62 percent (n = 29) systems.
Information about the evolutionary stage in which technologies
are assessed was provided by forty-one of the forty-seven insti-
tutions. Mostly “new technologies” (80 percent; n = 36) are
assessed.
Information about the definition of MDs used was ob-
tainable in twenty-two cases (47 percent). Most institutions
(41 percent, n = 9; e.g., FinOHTA) refer either to a general
definition for (health) technologies which include MDs (e.g.,
INAHTA/HTAi definition from HTA glossary) or to the EU-
Directives on MDs (36 percent; n = 8; e.g., AAZ). A small
proportion of institutions (18 percent; n = 4; e.g., OGYÉI TEI)
have (and provide) their own definition of MDs, often based on
national legal or regulatory provisions.
An explicit process for priority setting is used by 34 percent
(n = 16) of all institutions; for 26 percent (n = 12) a defined
prioritization process is not applicable because this is done by
the commissioning institution (e.g., MoH). In the case of an
existing explicit process, the following categories proposed by
Perleth et al. (15) are considered most often: medical-scientific
criteria (e.g., efficacy of intervention; 75 percent; n = 12),
criteria related to epidemiological significance of disease/
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Table 1. Overview of Information about Role and Scope of Included Institutions
Included institutions (n= 47)
Characteristics N (%)
Type of institution
Governmental institutions (national & regional) 17 (36%)
Independent research entities with function as governmental institution 11 (23%)
Independent research entities including academic or non-academic entities 8 (17%)
Ministries of Health/Social Affairs including a related department 4 (9%)
Social Health Insurance organizations 2 (4%)
Hospital unit/group 2 (4%)
Companies 1 (2%)
Non-departmental public body with legislative function 1 (2%)
Unclear/no information 1 (2%)
Types of technologies addressed
Medical devices (inclusion criterion) 47 (100%)
Drugs 41 (87%)
Procedures 39 (83%)
Systems 29 (62%)
All four types 25 (53%)
Evolutionary stage technologies assessed
New 36 (80%)
Established 27 (57%)
Emerging 17 (36%)
No information 6 (13%)
Explicit process for priority setting
Yes 16 (34%)
No∗ 5 (11%)
No information 14 (30%)
Not applicable∗∗ 12 (26%)
Criteria for priority setting (of those with an explicit process, n = 16)
Medical-scientific criteria 12 (75%)
Epidemiological significance of disease/burden of disease 11 (69%)
Economic criteria 10 (63%)
Other criteria that don’t fit in the categories (e.g. criteria depending on commissioning institution) 9 (56%)
Criteria concerning HTA production (e.g. feasibility) 7 (44%)
Societal criteria 5 (31%)
No information about specific criteria/too general for categorization 2 (13%)
Use of a definition of medical devices
Yes 22 (47%)
No∗ 2 (4%)
No information 23 (49%)
Definition of Medical devices (of those who provide a definition, n = 22)
Definition of technology/health technology (including INAHTA/ HTAi definition from HTA glossary) 9 (41%)
Regarding EU law (93/42/EEC, 90/385/EEC, 98/79/EC) 8 (36%)
Institutions own definition 4 (18%)
Regarding EU law in combination with own definition 1 (5%)
Note. Type of institution, evolutionary stage of technologies assessed, and definition of medical devices: own categorization based on available
information; Type of technologies addressed: based on categorization by Banta and Luce (14); Criteria for selection and prioritization of
technologies for assessment: own compilation based on Perleth et al. (15); ∗Identified information clearly stated that no explicit process for
priority setting/no specific definition of medical devices exists/is used;∗∗Prioritization carried out by the commissioning institution; For more
details on each institution, see Supplementary Table 2
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Table 2. Overview of Included Institutions and Information Identified Online about HTA
Report Production and Methodology
Included institutions
Characteristics (n = 47) N (%)
Produces its own reports
Producing 40 (85%)
Producing and commissioning 4 (9%)
Commissioning 2 (4%)
Unclear 1 (2%)
Reports available to the public/online
Yes 41 (87%)
Reports available for MDs∗
Yes 40 (85%)
Unclear∗∗ 1 (2%)
General information on the methodological approach
Yes 31 (66%)
Methodological guide/other official document available
Yes 23 (49%)
Methodological guide/other document for MDs available
Yes 5 (11%)
Methodological guide/document for economic evaluation
Yes 7 (15%)
Note. MDs = medical devices; HTA report production: Producing reports, including in
collaboration with other institutions/partnership; Reports defined as available even if
only abstract/summary of full reports are available (but not only the title);Methodology:
General information on methodological approach available on institutions Web site not
considered in this table; ∗For definition of MDs used in this table, see Henschke et al. (4);
∗∗Due to language barrier, no estimation possible; For more details on each institution,
see Supplementary Table 3.
burden of disease (e.g., importance of assessment; 69 percent;
n = 11), as well as economic criteria (e.g., better allocation of
resources; 63 percent; n = 10).
HTA Report Production
In total, forty of forty-seven institutions (85 percent) pro-
duce reports (in-house or in collaboration with other institu-
tions), two (4 percent) institutions commission reports (e.g.,
NIHR_NETSCC) and four (9 percent) institutions do both
(e.g., G-BA). For forty (85 percent) institutions, MD-specific
reports are publicly available (see Table 2).
Methodology
For 49 percent (n = 23) of included institutions, at least
one methodological guide or other official document detail-
ing applied methods was publicly available. In total, fifty-
four methodological documents could be identified. These
documents represent mainly (n = 36) general provisions for
the methodology/process underlying the institution’s outputs,
named for example “handbook” or “method manual,” or pa-
pers concentrating on methods for specific HTA domains, such
as economic evaluation and/or budget impact analysis (n = 6)
and stakeholder engagement (n= 1). A further three are regula-
tory documents. Only nine of the fifty-four documents concen-
trate solely on the evaluation of a specific type of technology,
namely MDs.
Identified Methodological Documents
From the identified fifty-four methodological documents, forty-
five were analyzed using the developed extraction tool (see
Figure 2 and Supplementary Table 4).
The following sections focus primarily on methodological
documents specifically addressing MDs (n = 9; see Figure 2),
aiming at describing their characteristics and key content. A
brief insight into provisions for MD assessment included in
general methodological documents (n = 36) is provided at the
start.
Analysis of General Methodological Documents Regarding Provisions for MDs
A common characteristic of all general methodological guides
included in the sample is that they are intended to be appli-
cable to all healthcare technologies within the institution’s re-
mit. However, two institutions state that within the assessment
process “[…] some aspects may be more relevant to particular
technologies than others” (HIQA) (16) or need to be adapted
(AOTMiT) (17). Three further institutions give more specific
information, recommending the use of MD registers (BIQG/
GÖG) (18), providing for a differentiated approach to topic se-
lection and prioritization (AAZ) (19) or highlighting organiza-
tional features that should be taken into account: “When rele-
vant, the technology description can furthermore include: who
is to operate the technology, technical and professional require-
ments of the operator…” (DACEHTA) (20).
Two general methodological documents explicitly include
additional sections for the evaluation of MDs. IQWiG’s general
methods guide (21) includes separate sections on the assess-
ment of nondrug interventions, diagnostic procedures, early di-
agnosis and screening, as well as determining the potential for
benefit of newly developed technologies considered for cov-
erage with evidence development (§137e, Social Code Book
V). However, several cross-references to general sections of the
document highlight that there are no fundamental differences in
the evaluation of these technologies when compared with phar-
maceuticals. The CRD guidance (22) for undertaking system-
atic reviews contains a chapter for diagnostic and prognostic
tests. According to the document “[…] much of the research on
diagnostic tests is in the form of test accuracy studies”. Thus,
the chapter discusses among others methods developed specif-
ically to deal with such studies.
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Figure 2. Overview of identified and analyzed methodological documents.
Note. MDs = medical devices; DACEHTA = Danish Centre for Health Technology Assessment; HAS = Haute Autorité de Santé; LBI = Ludwig Boltzmann Institute for Health Technology Assessment; NICE = National
Institute for Health and Care Excellence; ZiN = Zorginstituut Nederland; ∗Nine out of 45 general methodological documents could not be extracted due to language barrier and thus are not considered in the analysis.
Analysis of Methodological Documents Discussing MDs Only
The following synthesis has been structured to reflect differ-
ences in the objectives and target groups of documents detail-
ing the assessment of MDs only.
The documents of HAS (23), LBI (24), NICE (25–27),
and ZiN (28) describe the institutions own methodological ap-
proaches when assessing MDs, concentrating on diagnostic
technologies (25), medical/biomarker tests (24;28), and inter-
ventional/medical and surgical procedures (23;26;27). The ma-
jority of these documents concern full evaluations with the ex-
ception of the HAS document (23), which describes rapid as-
sessments. LBI’s (24) guidance aims to complement its general
internal manual for evidence synthesis on the specific issue of
effectiveness and safety of biomarker tests. Therefore, it cov-
ers only certain steps in the assessment which deviate or need
special attention.
Three further identified documents are primarily intended
as tools for other stakeholders. DACEHTA (29) provides a spe-
cific support tool for health professionals and health care man-
agers in the hospital setting. An HAS (30) document addresses
manufacturers, research organizations, and project developers
and aims to present methods and conditions for high-quality
clinical assessment of MDs. LBI’s one (31) is intended for de-
cision makers assessing diagnostic procedures. The latter pro-
vides recommendations and a list of guiding questions derived
from methods used by other institutions (e.g., IQWiG, NICE)
to appraise the evidence base for diagnostic technologies. In
these documents intended for other parties, some of the extrac-
tion elements of interest (e.g., re-assessment) are not addressed.
Nevertheless, a synthesis of the most relevant provisions from
all separate documents per domain is presented below (see Sup-
plementary Tables 5a and b for details).
(1) Assessment Elements. All institutional documents focus on clini-
cal effectiveness (including test accuracy) and safety. LBI (31)
and ZiN (28) also address clinical utility of diagnostic tests.
The former specifically refers to the six-level model for the
evaluation of diagnostic technologies by Fryback and Thorn-
bury. Moreover, NICE’s Diagnostics Assessment (DAP) (25)
and Medical Technologies Evaluation Programmes (DAP and
MTEP, respectively) (26), DACEHTA (29), and ZiN (28) con-
sider costs and/or economic evaluation. Social and organiza-
tional aspects are addressed by DACEHTA (29), LBI (24), and
NICE (25–27). Finally, ethical and legal aspects are taken into
account in LBI’s document (24).
(2) Evidence Procurement and Selection.
Assessment Base. HAS (23) and LBI (24) and the NICE Interven-
tional Procedures Programme (IPP) (27) base their assessments
on internally conducted research. Within NICE’s DAP the as-
sessment report is produced by an external assessment group
following the DAP manual (25). NICE MTEP (26), and ZiN
(28) expect applicants/sponsors to conduct a systematic re-
view and submit their assessments and underlying data for
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evaluation; in MTEP’s case this is carried out by the external
assessment center. DACEHTA (29) and LBI (31) suggest that
target stakeholders carry out a systematic review and refer to
their general documents for related methodological guidance.
Type of Evidence. All institutions state a clear preference for direct ev-
idence based on randomized controlled trials (RCTs), but also
accept or suggest other designs under certain circumstances. In
this respect, NICE IPP (27) states that “[…] the highest value
has traditionally been placed on evidence from meta-analysis
of RCTs or one or more well-designed and executed RCTs […]
In some instances, non-randomized studies may be more infor-
mative about outcomes”. LBI’s document on biomarker tests
(24) notes that for some specific research questions “[…] the
only evidence feasible and/or ethical will be from observational
studies and different evidence hierarchies may apply”, such as
the ones elaborated by the Australian National Health andMed-
ical Research Council.
ZiN (28) proposes a search for indirect evidence by means
of an “[…] analysis framework based on a comparison of the
usual test-plus-treatment-strategy and the proposed strategy”.
LBI (31) also considers linked evidence as an option for the
evaluation of diagnostic technologies but states clearly “[…]
that the use must be reasonably justified.” HAS (30) describes
alternative methods for conducting MD studies, including ex-
perimental designs such as Zelen’s design or the randomized
consent design, when conventional RCTs may be difficult to
implement (e.g., due to lack of direct evidence, randomization
or blinding). But they also clearly emphasize that “[…] The
choice of an observational study should remain the exception
[…]”.
Endpoints. All documents stress the importance of patient-relevant
endpoints regarding both assessment (LBI) (24;31), NICE IPP
(27) and clinical trial development (HAS) (30): “Evidence of
improved survival, reduced morbidity or improved quality of
life carry more weight in decision making than surrogate out-
comes” (27). If intermediate end points are used they “[…]
must have been justified and validated in previous studies”
(30). LBI (24) additionally states that an “accurate diagno-
sis is a prerequisite for a successful therapy, but it should
not be seen in isolation. Instead, the benefit to patients re-
sulting from diagnosis should be measured in patient-relevant
outcomes […]”.
Comparator. LBI (24;31), NICE DAP (25), and ZiN (28) refer to
a so called “standard” technology as the comparator to con-
sider. In the NICE MTEP manual (26) this is defined as “[…]
a similar or equivalent technology used as part of current man-
agement, but it can be no intervention”. In NICE IPP (27), the
comparator also depends on the circumstances and is either ac-
tive treatment or placebo. The HAS guide (30) discusses the
ethical acceptance of inactive controls in more detail.
(3) Appraisal of Evidence Quality. All documents include provisions on
the critical appraisal of evidence before conclusions are drawn.
For example, LBI (24), NICE DAP (25), and ZiN (28) recom-
mend the use of the QUADAS instrument or its revised iteration
when assessing the accuracy of tests. In addition, ZiN (28) and
LBI (24) use the GRADE instrument, including its adaptation
for diagnostic accuracy and prognostic studies.
(4) Review process and transparency. All institutional documents endorse
stakeholder involvement in the assessment production process
as well as a subsequent external review/consultation. Depend-
ing on the institution, draft and/or final reports will be pub-
lished online to ensure transparency.
(5) Re-assessment. Except for NICE MTEP (26) which “updates the
literature search every 3 years to ensure that relevant new ev-
idence is identified”, no specific intervals for the regular re-
assessment of MDs were given in the documents (where ap-
plicable). NICE (25;27) indicates that a renewed evaluation is
advisable if newer evidence becomes available and HAS (30)
suggests for an ideal assessment process surveillance and reg-
ular re-assessment of the use of a technology in practice.
(6) Knowledge Exchange and Transferability. NICEMTEP (26) and IPP (27)
explicitly state that they draw on other HTA reports for their
assessments. To ensure transferability of results differences be-
tween study and application context (e.g., patient population,
intervention setting) should be documented (NICE DAP) (25).
(7) Cost and Economic Evaluation. Detailed information could be ob-
tained from the documents on NICE’s DAP (25) and MTEP
(26). Within MTEP (26) cost-consequence analysis is used for
most technologies (including cost-saving diagnostics), whereas
DAP (25) undertakes complex assessments of diagnostic tech-
nologies using cost-effectiveness analysis.
(8) Other Device-specific Factors. The methodological documents of
HAS (30), NICE’s MTEP (26), and IPP (27) point out other rel-
evant factors with respect to the assessments of MDs, such as
the effect of operator or user experience on the results of a tech-
nique (“learning curve”) or dynamic pricing. NICE (26) un-
derlines that “The technology of devices may advance rapidly.
This means that both efficacy and safety outcomes reported in
the published literature may not accord with ‘current practice’
using technologically more advanced devices.” Thus, “[…] the
guidance may refer to the potentially important influence of dif-
ferent devices on the safety and/or efficacy of the procedure, or
to rapid technological developments described by the Specialist
Advisers, manufacturers or other sources” (26).
In NICE’s MTEP (25), “The Committee may make recom-
mendations for use of the technology in specific circumstances
only (e.g., by staff with certain training)”. HAS (30) recom-
mends that “During the development of a new medical device,
provisions must be made for training and learning plans”. Also
the volume of activity has to be taken into account because
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there is a “[…] significant association between favorable clini-
cal results and the doctor’s volume of activity […]”. In addition,
LBI (31) emphasizes research gaps in the field of diagnostic
technologies, for example, inaccurate reference standards.
DISCUSSION
Main Findings of the Study
Out of the eighty-four identified institutions, forty-seven are ac-
tively involved in the commissioning or performing of HTA
reports on MDs (assessment and/or appraisal). Sufficient infor-
mation was not publicly available for all institutions. Variabil-
ity still exists in the understanding of what the term MDs en-
tails, which is also reflected in different structural, procedural
and methodological elements among institutions. Although a
large number of general methodological documents were iden-
tified, only five institutions developed specific documents for
the assessment of MDs. Interestingly, five out of nine separate
documents focus on diagnostic technologies (including tests).
Similarities between documents for internal use are mainly re-
lated to the type of preferred evidence and outcome parameters
to be considered, appraisal of evidence quality and stakeholder
involvement. Differences mainly concern the assessment base
and comparator used, largely reflecting the different types of
devices evaluated (diagnostic versus therapeutic).
Institutions such as NICE and HAS also mention additional
parameters, such as learning curves or usage setting, as crucial
elements that should be considered. Only few institutions made
separate provisions for the assessment of MDs in their general
methodological documents. This reflects that certain evaluation
steps described in a general methodological paper apply to all
types of technologies, including MDs.
Comparison to Previous Literature and Current Activities
Several comparative studies have investigated HTA practices in
Europe (5–10), however, none with a specific focus on MDs.
The most recent example is the WHO Global Survey on HTA
from 2015, which includes fifty-three European countries (7).
In parallel to the present study, Ciani et al. (11) conducted a
survey on MD activities in non-EU HTA countries using a sim-
ilar approach (adapted for non-EU countries). They identified
thirty-six institutions whose remit included the evaluation of
MDs, and to which we will briefly compare our findings. How-
ever, Ciani et al. only consider twenty-seven of the identified
institutions to be MD-specific (i.e., with MD-specific elements
of organizational structure, process, or methods).
In the study by Ciani et al., mostly governmental institu-
tions could be identified as actively involved in MD assess-
ment (50 percent), which is more or less comparable to our
findings (36 percent). Fifty percent of thirty-six institutions use
an MD classification system/definition, which is also similar
to our findings (47 percent). Of interest, 70 percent of all in-
stitutions in Ciani’s survey have a process for priority setting,
compared with 34 percent in our sample. This difference may
be attributable to the fact that Ciani et al. included additional
participatory elements in their methodological approach, which
may have led to higher information availability on this issue;
publicly available information on priority-setting in our sample
was often lacking.
Ciani et al. reported nearly the same percentage of institu-
tions with publicly available methodological documents as our
study (50 percent versus 51 percent). However, only one institu-
tion has a MD-specific guide compared with five in our sample.
This could reflect the fact that more countries in Ciani’s sam-
ple are considered emerging settings regarding HTA and are,
therefore, less likely to have differentiated practices yet.
Recent activities by HTA networks, HTA institutions,
health service research institutions, and at regulatory level
show that the methodology of MD evaluation is being discussed
and taken forward: EUnetHTA developed a methodological
guideline for HTA of therapeutic MDs (32), the Belgian Health
Care Knowledge Centre demanded that efficacy requirements
for obtain a CE label for high-risk medical devices be raised
and transparency of clinical data underlying decision making
be granted (33) and the Royal Netherlands Academy of Arts
and Sciences provides guidance for research suitable for assess-
ing and evaluating benefits and performance tailored to various
types of devices (34). In Germany, the “Act to Further Develop
the Financial Structures and Quality in SHI”, enforced in 2015,
has been considered a door-opener for the benefit assessment
of MDs in conjunction with reimbursement (16). It introduces
a systematic approach to the evaluation of new methods incor-
porating the application of high-risk MDs.
Strengths and Limitations
The strengths of the presented research lie with the broad sys-
tematic approach adopted to identify institutions involved in
HTA in Europe combined with a focus on MDs, the collection
of a comprehensive range of information and the quality assur-
ance of all steps of the systematic approach by reviewer pairs.
However, reliance on published literature and online
sources alone meant that the study did not identify sufficient
information for all included institutions. This was due to both
a lack of publicly available information and language barriers.
Nevertheless, existing papers which used surveys to gather
data directly from the representatives of HTA institutions
faced the problem of low response rates, leading to similarly
partial overviews (6;7). Despite having been conceived to be
sufficiently broad, the systematic approach used to identify
institutions involved in HTA production in European countries,
may not have captured every institution involved in HTA pro-
duction. Overlooked institutions might include those not part of
international networks, not discussed in comparative publica-
tions or with a lack of publicly available information about their
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MD-specific focus. Despite our best efforts, we cannot rule
out the possibility that available information (including docu-
ments) was overlooked. As most of the institutions seem to use
their general methodological documents to assess MDs, a more
in-depth analysis of these would be necessary to get an overall
picture. In addition, due to the varying objectives and target
groups, the presented overview of results from MD-specific
documents does not necessarily depict all interesting details.
Implication for Policy and Research
In Europe there is a growing recognition of the importance of
methodological guidelines for HTA production, reflected also
in collaborative initiatives toward methodological standardiza-
tion (e.g., EUnetHTA) (22). However, the development and im-
plementation of specific methodological tools for the assess-
ment of MDs is still limited to the national level. Although
some HTA institutions already consider different approaches
for therapeutic and diagnostic technologies, other elements re-
lated to the use of MDs, such as device-operator interaction
and the level of device activity require further methodological
discussion. In conjunction with the efficient use of resources,
our results raise the question if fully separate methodological
guides are needed for the evaluation of MDs or if it is sufficient
to include supplementary specifications in the general manu-
als of each institution. We aim to further explore this issue:
an interview survey among selected HTA institutions included
in this overview with varying experience in the assessment of
MDs aims to contextualize and expand information obtained so
far and explore potential ideas for the future.
CONCLUSIONS
The work carried out aimed to identify and compare current
methods, processes, and institutional practices for the evalu-
ation of MDs in European countries to advance the debate
on whether existing assessment tools have to be modified or
adapted or if a wholly new approach is needed.
Despite growing consensus on the importance of the as-
sessment of especially high-risk devices, existing initiatives for
differentiated assessment practices, and relevant international
activities, specific methodological tools for the assessment of
MDs are rarely developed and implemented at the European
level. Separate additional signposts incorporated in existing
general methods guides may be sufficient for the evaluation of
MDs.
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